drugset / Trial / NCT00820105
ADX10059 Migraine Prevention Study
RandomizedParallel-groupDouble-blindPrevention
Summary
Evaluation of ADX10059 to prevent migraine attacks
Timeline
- Start
- 2008-12
- Primary completion
- 2010-01
- Completion
- —
Outcome
Outcome not reported
Stopped: “Incidence of abnormalities of liver function tests is higher than expected in this population.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RASEGLURANT | Small molecule | 25 mg | Oral |
| Subject | RASEGLURANT | Small molecule | 50 mg | Oral |
| Subject | RASEGLURANT | Small molecule | 100 mg | Oral |